secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001104659-24-103706
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq notifies TransCode of shareholder approval violation; adds to delisting risk
--------------------------------------------------------------------------------

- Received new Nasdaq deficiency letter on Sep 23, 2024 for failing to obtain shareholder approval for a deeply discounted offering.
- Offering on July 22, 2024 of 10M shares at $0.30/share (62% discount to Minimum Price) represented 137% of pre-transaction shares.
- Nasdaq determined discount >50% precludes public offering treatment, so shareholder approval was required under Rule 5635(d).
- This deficiency is an additional basis for delisting, beyond prior Minimum Bid Price and Stockholders' Equity deficiencies.
- Panel hearing scheduled for Oct 1, 2024 will consider all deficiencies; no assurance of continued listing on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924103706/0001104659-24-103706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924103706/tm2424982d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-103706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer